Overview of Haemopressin

Property	Description
Active ingredient	Terlipressin (as acetate salt)
Form	Sterile solution or lyophilized powder for intravenous (IV) injection
Pharmacological class	Vasopressin and analogues, Vasoactive peptide
Origin	Synthetic analogue

Haemopressin is the trade name for a medicine whose active substance is Terlipressin, a synthetic hormone analogue used primarily for its strong vasoactive properties. It is administered exclusively in critical, monitored settings to stabilize severely compromised circulatory function, acting as a potent tool for acute care.

What Type of Medicine is Haemopressin?

Haemopressin (Terlipressin) is a synthetic analogue of the natural human hormone Vasopressin, belonging to the pharmacological class of vasopressin and analogues. Terlipressin functions as a distinctive prodrug, a feature that is crucial for its efficacy in acute care environments. This means the compound is biologically inactive upon administration and must be gradually converted by the body's enzymes into the active compound, Lypressin. This chemical structure provides a significantly more sustained and controlled vasoconstrictive effect compared to the natural hormone, offering a crucial advantage in managing acute circulatory issues. This sustained action means the medicine works steadily to help support vital blood pressure over time.

Composition and Delivery Form

The active agent is Terlipressin, supplied as the acetate salt in either a sterile solution for injection or a lyophilized powder requiring reconstitution. The route of administration is strictly intravenous (IV) injection, which is necessary to ensure rapid, systemic delivery during circulatory emergencies. Because of the urgency of the conditions it addresses, Terlipressin must be delivered via an aqueous sterile solution directly into the circulation. This preparation form ensures the medicine immediately enters the bloodstream, where the process of conversion to its active form can begin without delay.

What is the General Purpose of This Vasoactive Agent?

The general purpose of Terlipressin is to act as a powerful and relatively selective vasoconstrictor, managing circulatory failure resulting from diminished vasomotor tone (loss of tension in the blood vessel walls). By inducing the tightening of blood vessels, especially within the splanchnic circulation (the vessels supplying the abdominal organs), the medicine effectively improves the overall circulating blood volume. This action is critical for raising mean arterial pressure and stabilizing the patient's cardiovascular system during acute crises, often employed when a patient's vasomotor tone has severely diminished.

Regulatory References

EMA Terlipressin Information

What side effects are possible with Haemopressin?

Possible Side Effects and Safety Information

The official safety profile for Haemopressin (Terlipressin) is structured around the physiological consequences of its powerful vasoactive effects, as defined in government regulatory labeling. Adverse reactions are formally classified by frequency and affected organ system, with the most serious concerns documented in special warnings.

Serious and High-Risk Adverse Reactions

The FDA label includes a Boxed Warning concerning the risk of serious or fatal respiratory failure and dyspnea (difficulty breathing), particularly in patients with existing fluid overload or Acute-on-Chronic Liver Failure (ACLF) Grade 3. Other serious adverse reactions documented in regulatory sources include ischemic events, such as Myocardial Infarction, Cerebrovascular Ischemia (stroke), and Mesenteric Ischemia, all related to the medicine's vasoconstrictive properties. Fatal cases of Sepsis/Septic Shock have also been reported in patients treated for Hepatorenal Syndrome Type 1, a documented safety concern

Common Adverse Reactions and Safety Patterns

Side effects classified as Very Common or Common include bradycardia (slowed heart rate), hypertension or hypotension, peripheral ischemia, headache, paleness, abdominal pain, nausea, and diarrhea. The regulatory profile notes that certain events, such as respiratory failure, have a documented median time to onset of approximately five days following the start of treatment in clinical trials.

Population-Specific Safety Constraints

The medicine is contraindicated in pregnancy due to the officially documented risk of embryo-fetal toxicity from inducing uterine contractions and reducing placental blood flow. Use is also restricted by regulatory safety notes in individuals with advanced renal dysfunction (e.g., serum creatinine ge 5.0 mg/dL), pre-existing hypoxia, or ongoing ischemic conditions due to the heightened safety risk in these specific populations.

Overdose and Emergency Response

Overdose and when to seek help

Overexposure to Haemopressin (terlipressin) is documented in regulatory labeling as a high-risk event, as the risk of Severe Circulatory Adverse Effects is dose-dependent. Immediate medical help must be sought if overexposure is suspected or if symptoms suggestive of severe complications occur.

Documented Overdose Profile

Element	Official Regulatory Statements
Documented overdose presentations:	Manifestations are expected to be similar to adverse reactions (e.g., headache, pallor, gastrointestinal distress); Acute Hypertensive Crisis is a dose-dependent effect.
Serious / life-threatening outcomes:	Ischemic Events (cardiac, peripheral, or cerebrovascular); Ventricular Arrhythmias; Serious or Fatal Respiratory Failure.
Population-specific overdose notes:	Patients with pre-existing hypertension or cardiopulmonary disease face a heightened risk of severe complications.

Emergency Actions Mandated by Regulators

Official overdose statements:

The medication must be discontinued immediately upon suspicion of overexposure or onset of ischemic symptoms [Source 1.5].
Appropriate symptomatic treatment must be initiated, as no specific antidote is known [Source 1.7].
Management of an acute hypertensive crisis involves the use of a vasodilator-type alpha-blocker, with intravenous clonidine cited as an example [Source 3.1].
Close professional monitoring of vital signs, electrolytes, and oxygen saturation is required during management of overexposure [Source 1.7].

Connection to the overall overdose profile: Regulatory documents define the overdose profile by its potential to cause severe, dose-dependent vascular events, such as ischemia and acute hypertension, which necessitates urgent clinical intervention. The mandated actions focus on discontinuing the drug and implementing specific supportive measures to manage these life-threatening circulatory and respiratory complications.

Therapeutic Uses of Haemopressin

What Haemopressin treats: main uses and benefits

Haemopressin contains the active substance terlipressin, a synthetic analogue of the naturally occurring hormone vasopressin. It is primarily used in hospital settings to manage acute, life-threatening complications related to liver disease and certain vascular conditions.

Bleeding Esophageal Varices

The primary application of Haemopressin is the treatment of bleeding esophageal varices. This condition occurs when blood vessels in the food pipe (esophagus) become enlarged and ruptured due to high blood pressure in the portal vein, a common complication of advanced liver cirrhosis.

Haemopressin works by constricting the smooth muscles of the blood vessels in the abdominal area. This narrowing reduces the blood flow to the liver and lowers the pressure within the portal venous system. By decreasing this pressure, the medication helps to control and stop the active bleeding from the varices.

Hepatorenal Syndrome (Type 1)

Haemopressin is also indicated for the treatment of Type 1 hepatorenal syndrome (HRS). This is a form of rapid kidney failure that occurs in individuals with severe liver cirrhosis or liver failure.

In patients with HRS, blood circulation is imbalanced; blood vessels supplying the kidneys constrict, while vessels in the abdomen dilate. Haemopressin helps correct this imbalance by constricting the abdominal vessels, which improves blood flow to the kidneys and can help restore some degree of renal function.

Benefits of Treatment

The use of Haemopressin provides several critical clinical benefits:

Hemostasis: It is effective in achieving early control of acute bleeding, which is vital for stabilizing patients before further endoscopic or surgical interventions.
Circulatory Stabilization: By redistributing blood flow, it helps maintain more stable blood pressure levels in emergency situations.
Renal Support: In cases of hepatorenal syndrome, it may improve kidney filtration rates, potentially providing a window of time for other treatments or liver transplantation evaluation.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Haemopressin (Terlipressin)

The medicine's eligibility is strictly defined by regulatory documents, primarily restricting its use to adults who meet the criteria for the labeled indication.

Classification	Restricted Populations	Basis for Limitation
Contraindicated	Pregnant women, patients with ongoing ischemia (coronary, peripheral, or mesenteric), and those with hypersensitivity to the drug [FDA/EMA Labeling].
Avoid Use	Patients with baseline serum creatinine 5.0 mg/dL (advanced renal dysfunction) or ACLF Grade 3 (severe liver failure), as benefit is unlikely and risks are high [FDA/EMA Labeling].
Not Recommended	Children and adolescents (pediatric use) due to limited safety and efficacy data; breastfeeding mothers are advised to discontinue nursing during treatment [EMA SmPC].
Use with Caution	Older adults (over 70 years), patients with a history of severe cardiovascular conditions, fluid overload, or pre-existing respiratory deficiencies [FDA/EMA Labeling].

Official eligibility statements require that the medicine must not be initiated in patients experiencing hypoxia (low oxygen saturation) or worsening respiratory symptoms until stabilization. Use in adults must be strictly monitored, especially for risks that could affect eligibility for liver transplantation.

What should I know about interactions with other medicines?

The official regulatory documents for Haemopressin (Terlipressin) define its interaction profile primarily through pharmacodynamic reinforcement and specific procedural constraints. The profile establishes the absence of significant pharmacokinetic interactions.

Documented Interaction Patterns

Interaction Category	Interacting Substances / Outcome
Cardiac Risk Reinforcement	Co-administration with medicines that prolong the QT interval (such as certain antiarrhythmics, antibiotics, or tricyclic antidepressants) requires extreme caution due to the risk of ventricular arrhythmias, including Torsade de pointes. This cardiac electrical risk is similarly heightened by combining with medicines that may cause Hypokalaemia or Hypomagnesemia.
Hemodynamic Effects	Concomitant use with medicines known to induce bradycardia (e.g., Propofol or Sufentanil) may cause a severe reduction in heart rate and cardiac output. Combining with non-selective beta-blockers is documented to increase the hypotensive effect on the portal vein pressure.
Metabolic Interactions	None Documented. Regulatory information states the drug's metabolism by tissue peptidases is unlikely to be affected by other medicinal products, establishing the lack of CYP- or transporter-mediated interactions.

Administration Restrictions

The sterile solution must not be mixed with any other medicinal products in the same injection container or line, as official compatibility studies are absent. Furthermore, no specific interactions with food, alcohol, herbal products, or supplements are documented in the authoritative prescribing information.

Mechanism of Action

How Haemopressin Works

Haemopressin (Terlipressin) exerts its action through a multi-step pharmacodynamic mechanism involving enzymatic conversion and targeted receptor agonism, leading to systemic changes in blood circulation.

1. The Sustained Action of the Prodrug Mechanism

The medicine is initially an inactive prodrug that must be slowly and continuously broken down by endothelial enzymes (exopeptidases) in the bloodstream. This enzymatic conversion releases the active molecule, Lypressin. This prodrug-based mechanism dictates the duration of action, providing a crucial reservoir of the active substance that ensures the resulting physiological effect remains sustained over several hours, which is a consequence of its extended half-life.

2. Targeted V1 A Receptor Activation and Vasoconstriction

The active Lypressin acts as an agonist (activator) on V1 A receptors, which are densely located on the vascular smooth muscle cells. Activation of these receptors triggers a G q-protein cascade, significantly raising the level of intracellular calcium (, Ca^2+). This surge in calcium directly leads to the contraction (tightening) of the blood vessel walls, which mechanistically increases the body's Systemic Vascular Resistance (, SVR).

3. Modulation of Splanchnic Circulation

The vasoconstriction is particularly pronounced within the splanchnic circulation (the blood vessels of the abdominal organs). This targeted tightening reduces blood flow in this area, causing a redistribution of circulating blood volume from the abdominal vessels back toward the central (core) circulation. This volume shift, combined with the generalized increase in SVR, results in the physiological consequence: an elevation of the Mean Arterial Pressure (, MAP).

Dosage and Administration Information

How to use Haemopressin

Haemopressin (Terlipressin) is administered intravenously (IV), solely for use in acute, monitored care settings. The medicine is supplied as a lyophilized powder and must be reconstituted prior to use with 0.9% Sodium Chloride Injection. Administration occurs via a slow IV bolus injection over approximately two minutes; certain clinical regimens also outline protocols for continuous intravenous infusion.

Dosing regimens are rigid and dependent on the condition being addressed. For Hepatorenal Syndrome (HRS), the starting dose is 0.85 mg every six hours (Q6H) for the first three days. The dosage is subject to adjustment on Day 4 based on the patient's change in serum creatinine (SCr) level. If the reduction in SCr is insufficient, the dose is increased to 1.7 mg every six hours. Conversely, protocols for managing bleeding esophageal varices typically start with 2 mg every four hours, which is then reduced to a 1 mg maintenance dose once initial stability is achieved.

Treatment is time-limited, generally not exceeding a maximum of 14 days for HRS, and must be discontinued earlier if SCr values meet the established criteria for treatment success, or if SCr returns to or exceeds the baseline value on Day 4. For HRS treatment, simultaneous co-administration with Albumin is required. Prior to the initial dose, the patient's oxygen saturation (SpO2) must be assessed as a mandatory procedural step.

Recent Clinical Evidence

Evidence for use in Hepatorenal Syndrome (HRS-AKI)

Research exploring Haemopressin (Terlipressin) has focused on large Randomized Controlled Trials (RCTs) involving adults with severe, rapid kidney impairment (HRS-AKI) in the context of circulatory dysfunction. Studies monitored outcomes such as verified HRS reversal (a measured improvement in kidney biomarkers like serum creatinine) and the avoidance of Renal Replacement Therapy (RRT). Measured responses were met more frequently among patients in the study group compared to the placebo group. While survival findings were mixed across the full study population, research reported that the specific subgroup of patients who achieved the measured HRS reversal had higher measured survival rates at 90 days. The primary outcome measured by researchers is the specific reduction in serum creatinine used to define reversal.

Evidence for use in Acute Variceal Bleeding (AVB)

The evidence base consists of RCTs and meta-analyses exploring the medicine as an adjunctive therapy alongside standard endoscopic procedures for acute esophageal hemorrhage. Researchers examined outcomes related to episodic changes, such as hemostasis (stopping the bleeding) and the rate of rebleeding. Studies reported patterns suggesting that the inclusion of the medicine was associated with a more frequent attainment of initial bleeding control and a lower measured frequency of rebleeding events compared to study groups that received no vasoactive agent. Comparative studies with other vasoactive drugs indicated that measured differences in outcomes were not consistently found.

Research Gaps and Areas of Uncertainty

For both indications, follow-up durations were limited in the major trials, and long-term effects are not fully established. Studies on HRS-AKI monitored recurrence rates and noted that the measured effect is not sustained after discontinuation for some patients. Furthermore, the results apply only to the adult populations studied, as high-risk patients (e.g., advanced Acute-on-Chronic Liver Failure) were often excluded, making data for these subgroups insufficient. The primary limitation across the evidence is the lack of research focused on long-term survival benefits.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Haemopressin (FAQ)

Q: Is Haemopressin the same type of drug as Vasopressin?

A: Haemopressin (Terlipressin) is classified as a synthetic analogue of the natural human hormone Vasopressin. Official product information notes that Haemopressin functions as an inactive prodrug, meaning the body must first slowly convert it into the active molecule, Lypressin, to produce the desired effect.

Q: What's the difference between Haemopressin and other similar vasoconstrictors?

A: A key difference, noted in regulatory reviews, is its classification as a prodrug. This design allows the active component to be released slowly and continuously in the bloodstream, providing a more sustained and controlled vasoconstrictive effect over several hours compared to other similar medicines.

Q: How long does the effect of Haemopressin last in the body?

A: Studies on the medicine's mechanism indicate that the sustained release from the prodrug reservoir ensures the resulting physiological effect remains effective for several hours. This feature, noted in official documents, provides a sustained effect, helping to support vital signs.

Q: Can Haemopressin interact with common painkillers or cold medicines?

A: Authoritative drug information does not specifically document interactions with common over-the-counter painkillers or cold medicines. However, the regulatory label indicates caution is required when the medicine is used with any medication that may cause a significant drop in potassium or magnesium levels, as this can increase cardiac risks.

Q: Are there any major drug interactions to be aware of with Haemopressin?

A: Regulatory documents highlight major precaution areas. These include co-administration with medicines that are known to prolong the QT interval (due to the risk of serious arrhythmia) and medicines that induce bradycardia (slowed heart rate).

Q: Does taking Haemopressin require any special patient preparation?

A: Official procedural steps require certain assessments before the medicine is administered. For example, the patient's oxygen saturation ( SpO2) must be evaluated prior to the initial dose. For the treatment of Hepatorenal Syndrome, co-administration with Albumin is also required.

Q: Why do doctors choose Haemopressin over other drugs for certain types of bleeding?

A: The choice is linked to its unique prodrug mechanism, which offers a sustained and controlled vasoconstrictive effect over several hours. This prolonged action helps stabilize the patient's cardiovascular system and support vital blood pressure during acute crises.

Q: Is Haemopressin only given in emergency situations?

A: The medicine is strictly administered in acute, monitored care settings, such as a hospital. While the conditions it addresses are urgent, treatment is time-limited, typically not exceeding 14 days, rather than being a single-use emergency measure.

Q: Are headaches a common complaint when using Haemopressin?

A: Yes, official regulatory safety profiles classify headache as a Common adverse reaction. This means it is among the side effects most frequently reported in clinical studies.

Q: Is it normal to feel dizzy or lightheaded after getting Haemopressin?

A: Changes in blood pressure and bradycardia (slowed heart rate) are common side effects noted in the safety profile. Lightheadedness or dizziness may sometimes be associated with these effects, which is why patients are closely monitored during administration.

Q: Are there certain foods or drinks I need to avoid while on Haemopressin?

A: According to the authoritative prescribing information, there are no specific interactions documented with food, alcohol, or herbal products. However, the medicine is administered in acute care where food and drink intake may already be restricted.

Q: Is Haemopressin used for bleeding outside of a hospital setting?

A: No. Official guidance states that the medicine must be administered intravenously (IV) and is solely for use in acute, monitored care settings. This is typically within a hospital or specialized critical care environment.

Q: Can I drive or operate machinery after receiving Haemopressin?

A: Official product documentation states that no studies on the effects on the ability to drive and use machines have been performed. Due to the nature of the conditions treated and potential side effects, this activity is generally avoided.

Q: Is Haemopressin safe for children or adolescents?

A: The use of Haemopressin in children and adolescents (pediatric use) is Not Recommended by regulatory bodies. This restriction is due to the limited safety and efficacy data available for these specific populations.

Q: Does Haemopressin have any known interactions with herbal supplements?

A: Regulatory prescribing information states that no specific interactions with herbal products or supplements are documented. This suggests there is no formal evidence of a direct interaction profile.

Q: How is the dose of Haemopressin usually decided by a doctor?

A: The dosing regimen is standardized based on the condition being treated. For example, in Hepatorenal Syndrome, the dose may be adjusted on Day 4 based on the patient's change in serum creatinine (SCr) level, a key measure of kidney function.

Q: Can Haemopressin cause a temporary change in skin color or temperature?

A: Yes, paleness is documented as a Common side effect in regulatory documents. This is a physiological effect related to the drug's powerful vasoconstrictive properties, which temporarily reduces blood flow to the skin.

Q: What should I tell my doctor before starting Haemopressin treatment?

A: The prescribing information indicates that doctors need to be aware if a patient is pregnant or has a history of ongoing ischemic conditions (such as heart attack or stroke), advanced renal dysfunction, or severe respiratory symptoms.

Q: Does Haemopressin affect how my other regular medications work?

A: Official information regarding its metabolism suggests that the drug is unlikely to be affected by other medicines. This is because it is metabolized by tissue peptidases, establishing a lack of common metabolic drug interactions.

Q: Why would someone need a medicine like Haemopressin?

A: The general purpose, according to regulatory documents, is to act as a powerful vasoconstrictor to manage circulatory failure. It works by inducing the tightening of blood vessels to improve overall circulating blood volume and stabilize the patient’s cardiovascular system during an acute crisis.

Q: Does Haemopressin come in different strengths or formulations?

A: Yes, regulatory documents indicate the medicine is supplied as the active agent Terlipressin in either a sterile solution for injection or a lyophilized powder that requires reconstitution before use.

Q: Can Haemopressin interact with alcohol or recreational substances?

A: No specific interactions with alcohol or recreational substances are documented in the authoritative prescribing information. The medicine is, however, administered in a closely monitored care setting.

Q: How long does it take for Haemopressin to be cleared from the body?

A: The medicine is designed with an extended half-life to ensure the physiological effect is sustained over several hours via its prodrug mechanism. Specific clearance times for patients are not broadly summarized in general patient information.

Q: Are there any known side effects on the digestive system from Haemopressin?

A: Yes, the official safety profile documents common adverse reactions that affect the digestive system. These include abdominal pain, nausea, and diarrhea.

Q: What does the patient information leaflet say about side effects of Haemopressin?

A: The leaflet states that very common/common side effects include slowed heart rate, changes in blood pressure (high or low), headache, paleness, abdominal pain, nausea, and diarrhea. It also includes serious warnings about respiratory issues and ischemia.

Q: Why might a doctor stop giving Haemopressin after a certain time?

A: Treatment is intended to be time-limited, generally not exceeding a maximum of 14 days, as noted in the regulatory documents. Treatment may also be discontinued earlier if the patient achieves the measured criteria for treatment success (e.g., specific improvement in kidney markers).

Q: Is there a generic version of Haemopressin available?

A: Haemopressin is the trade name for the active substance Terlipressin. Terlipressin is the recognized generic name for the compound.

Q: Does Haemopressin affect blood sugar levels?

A: Regulatory safety information indicates that changes in blood sugar have been reported. Rare cases of hyperglycaemia (high blood sugar) have been documented during treatment with Haemopressin.

Q: What safety measures are in place when administering Haemopressin?

A: Due to its potent effects, safety measures include mandatory assessment of oxygen saturation ( SpO2) before the first dose. Continuous patient monitoring is necessary throughout treatment to quickly identify and manage any potential serious events like ischemia or hypoxia.

How should Haemopressin be stored and disposed of?

How to Store and Dispose of Haemopressin?

Haemopressin (terlipressin) must be stored under specific environmental and packaging conditions as defined by regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store unopened vials in a refrigerator at 2 C to 8 C (36 F to 46 F). Do not freeze.
Protection	Must be stored in the original carton to protect the contents from light.
Stability	The solution, once reconstituted, is stable for up to 48 hours when stored under refrigerated conditions.
Child Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Any unused or expired Haemopressin product must be discarded in accordance with local requirements for pharmaceutical waste. The medicine must not be disposed of via wastewater or in ordinary household trash.

Haemopressin